chufangao/CTO huggingface dataset:
Clinical trial NCT03322657: Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
Official title: Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 69.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-14
Primary completion date: 2020-12-31
Completion date: 2021-02-01
Clinical trial NCT03158116: The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas
Official title: A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube.
Acronym: A-PACT
Sponsor: UCSF Benioff Children's Hospital Oakland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: IRB application expired.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-01
Primary completion date: 2020-02-20
Completion date: 2020-02-20
Limitations and caveats: The study has limitations with the primary one being it is a very small study. The intention was to have a larger study multi-center study. However, due to multi-site institutional research logistics and administrative bureaucracy, expanding the study was not possible.
Plan to share individual participant data: NO
Clinical trial NCT02435173: Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Official title: An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-08-24
Primary completion date: 2021-08-16
Completion date: 2021-08-16
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03879707: Improving Sleep Quality After Total Joint Arthroplasty ( TJA)
Official title: Improving Sleep Quality After Total Joint Arthroplasty ( TJA)
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Investigator elected not to proceed with project
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT04974580: Research and Innovation to Stop E-cigarette/Vaping in Young Adults
Official title: Young Adult Vaping Cessation: A Randomized Trial Examining Phone Coaching, Text-based Digital Intervention, and Nicotine Replacement Therapy
Acronym: (RISE)
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 508.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-07-28
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: NO
Clinical trial NCT05571540: Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Official title: An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)
Sponsor: Kunming Hope of Health Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The PI decides to stop.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-01
Primary completion date: 2024-01-31
Completion date: 2024-10-31
Clinical trial NCT02270957: Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
Official title: Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)
Acronym: ABC
Sponsor: Oklahoma Medical Research Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-01-31
Primary completion date: 2018-12-31
Completion date: 2021-12-31
Plan to share individual participant data: YES
IPD sharing description: We will share de-identified results through an application process, linked to our institutional research cohorts, where there is a standard operating procedure approval process where research is deemed to be appropriate and relevant to SLE
IPD time frame: June 2021-May 2023
IPD access criteria: contact the PI at joan-merrill@omrf.org
Clinical trial NCT02523898: Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant
Official title: Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial
Sponsor: Semnan University of Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: unfortunately due to COVID 19and social problems following it,we were unable to reach the estimated sample size.Evantually we could have only 151 patients .
Enrollment: 388.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Clinical trial NCT04205071: Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer
Official title: Pilot Trial of Acute Effect of Lorcaserin to Reduce Patient-Reported Symptoms of Taxane- and Oxaliplatin-Induced Peripheral Neuropathy
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: PI decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT05908513: NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM
Official title: Randomized Study on N-acetylcysteine Treatment and Outcomes in Patients With Advanced Atherosclerotic Heart Diseases and Diabetes Mellitus (RENEWAL)
Acronym: RENEWAL
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lack of available resources needed to conduct study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-15
Primary completion date: 2021-10-15
Completion date: 2021-10-15
Plan to share individual participant data: NO
IPD sharing description: Due to the confidential information included in this study, all data won't be shared for now.
Clinical trial NCT03018704: Topiramate Treatment of Alcohol Use Disorders in African Americans
Official title: Topiramate Treatment of Alcohol Use Disorder in African Americans
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: In ability to recruit
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Limitations and caveats: The study was stopped by the funding agency due to difficulty recruiting during COVID pandemic
Plan to share individual participant data: NO
Clinical trial NCT04342897: A Study of LY3127804 in Participants With COVID-19
Official title: A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial terminated for futility.
Enrollment: 95.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-20
Primary completion date: 2020-10-12
Completion date: 2020-10-12
Baseline population: All randomized participants who received at least 1 dose of study drug.
Limitations and caveats: The study was terminated for futility reason.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
IPD access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Clinical trial NCT05130398: Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
Official title: A Phase 1/2, Randomized, Controlled Open-label Trial to Evaluate the Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Healthy Children Aged 1 to 12 Years and in Their Relatives Living in Lambaréné, Gabon
Acronym: EBOLAPED
Sponsor: Centre de Recherche Médicale de Lambaréné (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-04-09
Primary completion date: 2021-09-08
Completion date: 2022-08-09
Plan to share individual participant data: YES
IPD sharing description: The Principal investigator or his designee will be the data manager with responsibility for delegating the receiving, entering, cleaning, querying, analysing and storing all data that accrues from the study. All data will be entered in paper case record forms and transcribed by double entry into an electronic database. This includes safety data, laboratory data (both clinical and immunological) and outcome data.
IPD time frame: From preliminary intererim analysis until the final report fo the study.The site owns the data and it is agreed that publication will occur in a timely manner.
IPD access criteria: All files and source documents will be kept confidentially in locked safety cabinets. The Principal investigator, co-investigators and clinical research nurses will have access to records. The investigators will permit authorized representatives of the sponsor, regulatory agencies and the monitors to examine (and when required by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress.
Clinical trial NCT05451095: A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
Official title: A Randomized, Placebo Controlled, Double-blind, Double-dummy, Three-way Crossover Trial to Investigate the Effect of Two Doses of BI 474121 on Ketamine Induced Cognitive Deficits in Healthy Male Subjects
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Termination of project
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-11-07
Primary completion date: 2023-06-05
Completion date: 2023-06-20
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to:~https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Official title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor R \& D Strategy Adjustment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-19
Primary completion date: 2022-02-18
Completion date: 2022-02-18
Clinical trial NCT03884296: Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood
Official title: Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood
Acronym: FLU-Tonsil
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Not feasible to enroll participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-15
Primary completion date: 2023-11-17
Completion date: 2023-11-17
Plan to share individual participant data: NO
Clinical trial NCT03291054: Epacadostat and Pembrolizumab in Patients With GIST
Official title: A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal Tumors
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study ended prematurely at the request of the funding sponsor.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-28
Primary completion date: 2020-08-19
Completion date: 2020-08-19
Baseline population: Data was not analyzed or disclosed in an effort to protect subject confidentiality (n=1).
Plan to share individual participant data: NO
Clinical trial NCT04868890: A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
Official title: A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
Sponsor: Ampio Pharmaceuticals. Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The AP-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint.
Enrollment: 200.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-22
Primary completion date: 2022-02-16
Completion date: 2022-04-13
Limitations and caveats: The AP-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint.
Clinical trial NCT02892071: Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma
Official title: Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Our fellow completed the program before we were able to start the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-31
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04199754: IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy
Official title: Pilot Study of Intravenous Contrast-Enhanced Cone Beam Computed Tomography (CT) in Patients Receiving Radiotherapy
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Slow accrual rate due to national contrast shortage
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-01
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Plan to share individual participant data: NO
Clinical trial NCT03982368: A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
Official title: A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 261.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-10
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Baseline population: Full analysis set (FAS): The FAS consisted of all patients randomized who took at least 1 dose of IMP and who had at least 1 postbaseline efficacy measurement for the primary endpoint.
Clinical trial NCT03068130: Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Official title: An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Acronym: RANGER
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Enrollment: 261.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-18
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Baseline population: Safety population (all patients who received at least 1 dose of bardoxolone methyl)
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT03951805: A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
Official title: A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Insulin-naïve Subjects With Type 2 Diabetes Mellitus
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 205.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-05-09
Primary completion date: 2019-12-12
Completion date: 2020-01-17
Baseline population: The full analysis set included all randomised participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04522466: Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients
Official title: Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients
Acronym: PREAVIS
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Stop of the study by competent authority (ANSM)
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-03
Primary completion date: 2020-05-28
Completion date: 2020-05-28
Plan to share individual participant data: NO
Clinical trial NCT04811924: The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients
Official title: The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients
Sponsor: Ciusss de L'Est de l'Île de Montréal (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Change in methodolody.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-26
Primary completion date: 2023-02-22
Completion date: 2023-02-22
Clinical trial NCT04144335: N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV
Official title: A Phase 1B Study of N-803 Combined With the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Contact issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-01
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT01773395: GVAX vs. Placebo for MDS/AML After Allo HSCT
Official title: A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recommendation by the Data and Safety Monitoring Board due to efficacy concerns
Enrollment: 123.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-08
Primary completion date: 2020-12-11
Completion date: 2021-11-24
Baseline population: Baseline Analysis Population only includes participants who received at least 1 GVAX or placebo vaccine
Clinical trial NCT04851834: NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Official title: A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)
Sponsor: Xennials Therapeutics Australia Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated by IP Holder (collaborator), PinotBio Inc.
Enrollment: 12.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-08-25
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Clinical trial NCT04968938: Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
Official title: A Phase 2, Open Label Study of the Safety and Effectiveness of MDMA-assisted Therapy for Participants With Posttraumatic Stress Disorder
Acronym: NUMCAP1
Sponsor: Lykos Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decided not to pursue the study. Study ended prior to study start.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-31
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: YES
IPD sharing description: We will share outcome data appearing in any published reports upon request.
IPD time frame: Data and study-related documents will be available when the database has been locked and data has been unblinded.
IPD access criteria: Interested persons should correspond with the central contact for the multisite study.